Akorn Reports Preliminary Fourth Quarter and Full Year 2014 Results
February 26, 2015 07:00 ET
|
Akorn, Inc.
- Fourth Quarter GAAP EPS of $0.29; Non-GAAP Adjusted EPS of $0.50 -
- 2015 Revenue Guidance of Between $960 million and $980 million -
- 2015 Non-GAAP Adjusted EPS Guidance of $1.88 - $1.98 -...
Akorn Announces Fourth Quarter 2014 Earnings Release and Conference Call Information
January 29, 2015 07:00 ET
|
Akorn, Inc.
LAKE FOREST, Ill., Jan. 29, 2015 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), expects to release fourth quarter 2014 earnings before the U.S. equities markets open on Thursday, February 26, 2015. In...
Akorn Receives FDA Approval for Phenylephrine HCl Ophthalmic Solution
January 20, 2015 07:00 ET
|
Akorn, Inc.
LAKE FOREST, Ill., Jan. 20, 2015 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), today announced that it has received approval from the U.S. Food and Drug Administration (FDA) on the Company's New Drug...
Akorn Confirms Generic Durezol(R) Patent Challenge
January 15, 2015 17:30 ET
|
Akorn, Inc.
LAKE FOREST, Ill., Jan. 15, 2015 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration...
Akorn to Present at the 33rd Annual J.P. Morgan Healthcare Conference
December 19, 2014 09:30 ET
|
Akorn, Inc.
LAKE FOREST, Ill., Dec. 19, 2014 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a specialty generic pharmaceutical company, announced today that Raj Rai, Chief Executive Officer, will provide an...
Akorn Reports Preliminary 2014 Third Quarter Results
November 06, 2014 07:30 ET
|
Akorn, Inc.
LAKE FOREST, Ill., Nov. 6, 2014 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a niche pharmaceutical company, today reported preliminary financial results for the fiscal third quarter ended September...
Akorn, Inc. Announces Third Quarter 2014 Earnings Release and Conference Call Information
October 21, 2014 11:02 ET
|
Akorn, Inc.
LAKE FOREST, Ill., Oct. 21, 2014 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX) will host a conference call on Thursday, November 6, 2014, to discuss third quarter 2014 results followed by a Q&A...
Akorn Acquires Xopenex(R) (levalbuterol HCI) Inhalation Solution From Sunovion
September 30, 2014 16:15 ET
|
Akorn, Inc.
LAKE FOREST, Ill., Sept. 30, 2014 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a niche pharmaceutical company, today announced that it has signed a definitive agreement ("Agreement") to acquire...
Akorn Completes Acquisition of VersaPharm
August 12, 2014 08:50 ET
|
Akorn, Inc.
LAKE FOREST, Ill., Aug. 12, 2014 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a niche pharmaceutical company, announced today that it has completed its previously announced acquisition of VPI...
Akorn Reports Preliminary 2014 Second Quarter Results
August 05, 2014 06:05 ET
|
Akorn, Inc.
LAKE FOREST, Ill., Aug. 5, 2014 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a niche generic pharmaceutical company, today reported preliminary financial results for the second quarter ended...